ABSTRACT. The effect of the administration for 7 days of valproate (500 mg/kg/day) or valproate (500 mg/kg/day) plus L-carnitine (200 mg/kg/day) on carnitine concentrations in serum, red blood cells, muscle, liver, and urine was evaluated. In the serum and muscle of the valproic acid (VPA) group, free carnitine levels decreased, while acylcarnitine levels and acyllfree ratio increased, when compared to those of the control. When L-carnitine was given to the VPA group, the free carnitine levels increased in the serum, muscle, and liver, and the acyllfree ratio decreased in all tissues when compared to those of the VPA group. The mean of free carnitine level in urine of the VPA group was not different but acylcarnitine increased when compared to values of controls, and after the supplementation with L-carnitine the acylcarnitine (from day 4 to 7) levels were decreased compared to the VPA group. The serum 8- VPA has become a useful drug for the treatment of epilepsy. However, there are several reports about side effects which include hyperammonemia, hyperglycinemia, and a Reye-like syndrome (1-3). Recently, Ohtani et al. (4) reported that hypocarnitinemia occurred in patients treated with VPA. We also reported a patient with a Reye-like syndrome associated with the administration of VPA, and the patient showed hypocarnitinemia with increased urinary excretion of acylcarnitine (5, 6). We suggested that the hypocarnitinemia which appeared in the acute stage of Reye's syndrome or Reye-like syndrome including VPAinduced hepatic encephalopathy was an important observation which might relate to the pathogenesis of these diseases (6).
VPA has become a useful drug for the treatment of epilepsy. However, there are several reports about side effects which include hyperammonemia, hyperglycinemia, and a Reye-like syndrome (1-3). Recently, Ohtani et al. (4) reported that hypocarnitinemia occurred in patients treated with VPA. We also reported a patient with a Reye-like syndrome associated with the administration of VPA, and the patient showed hypocarnitinemia with increased urinary excretion of acylcarnitine (5, 6). We suggested that the hypocarnitinemia which appeared in the acute stage of Reye's syndrome or Reye-like syndrome including VPAinduced hepatic encephalopathy was an important observation which might relate to the pathogenesis of these diseases (6) .
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investigated the carnitine metabolism of VPA-treated rats supplemented with L-carnitine.
MATERIALS AND METHODS
VPA was a generous gift from Kanebo Yakuhin Co., Tokyo, Japan and L-carnitine was purchased from Sigma Tau Co., Italy.
[l-C'4]-acetyl-CoA was purchased from New England Nuclear, Boston, MA and Carnitine acetyl transferase was obtained from Boehringer-Manheim, Houston, TX.
The animals usefi, were male Wistar rats weighing 180 g to 200 g. They were fed standard commercial rat food (total carnitine: ~0 . 1 nmol/g dry weight, MF, Kitayama Rabesu Co., Kyoto, Japan) and drank water ad lzbltum during the study period.
Twenty-six rats were divided into four groups: the first group of eight rats received normal saline (1 ml divided into two doses/ day); the second group of eight rats received VPA (500 mg/kg, divided into two doseslday); the third group of six rats received VPA (500 mg/kg, divided into two doses/day) plus L-carnitine (200 mglkg, divided into two doseslday); the fourth group of four rats received L-carnitine (200 mg/kg, divided into two doses/ day). All rats were received intraperitoneal injections twice a day for 7 days and were made to fast overnight following the final injection. Nine rats, three from each three groups, were transferred to metabolic cages for urine collection. The rats were anesthetized with pentobarbital and blood samples were obtained via the carotid artery.
Free and total carnitine levels in serum and in the homogenized muscle and liver were measured by the method of McGany and Foster (7). RBC carnitine concentration was measured by the method of Borum et al. (8) . Protein was determined by the method of Lowry et al. (9) . Creatinine concentrations in urine were measured by the method of Folin-Wu (Creatinine Test Wako, Wako Junyaku Kogyo Co.) (10). P-OH-butyrate levels in serum were measured by the diazo-method (Keton Test Sannwa, Sannwa Kagaku Kenkyusho Co.) (1 I). The results were analysed statistically with Tukey's method.
RESULTS
All rats survived the experiments. There were no significant differences in body weight gain in any of the experimental groups. Serum, RBC, muscle, and liver carnitine concentrations in three or four groups were shown in Table 1 . In the serum and the muscle, VPktreated rats clearly showed reduced concentrations of free carnitine, increased levels of acylcarnitine, and increased ratios of acylcarnitine to free carnitine (acyl/free ratio) when compared to controls. However, there was no difference in the liver carnitine concentration between the control and VPAtreated rats. When the L-carnitine was given to VPA-treated rats, the concentration of free carnitine and acylcarnitine in the serum and the liver increased, and there was no difference in the muscle free and acylcarnitine levels compared to those of the controls. In RBC there were no significant differences in free, acyl, and total carnitine concentrations among four groups except the acyl/ free carnitine ratio. The concentrations of carnitine in the urine of four groups are shown in Table 2 . Free carnitine levels in urine of the VPAtreated animals were not different when compared to those of the controls. However acylcarnitine levels in VPA-treated and VPA plus L-carnitine-treated rats increased when compared to control animals. The mean acylcarnitine level in urine of the VPA plus L.-carnitine group from day 4 to 7 was lower than that in VPA-treated group. The acyl/free carnitine ratio in the VPA group was significantly higher than that in either the control or VPA plus I.-carnitine group. Urinary free, acyl, and total carnitine concentrations in the VPA plus I--carnitine group increased daily.
In control, VPA-treated rats, and VPA plus L-carnitine-treated rats, serum 6-OH-butyrate levels were 1.93 f 0.22, 1.0 l + 0.53, and 2.14 + 0.5 mM/I, respectively. The blood VPA concentration in groups VPA and VPA plus L-carnitine were less than 5 g / d l in all samples on the 8th day.
DISCUSSION
VPA is a branched chain fatty acid which closely resembles 4-pentenoic acid, a strong inhibitor of fatty acid oxidation (12).
Mortersen et a/. (13) reported on C6-Clo-dicarboxylic acidurias in patients and rats treated with VPA. Coude el a/. (14) showed that VPA inhibited oxidation of [l-C14]-palmitate in isolated rat hepatocytes and decreased ketogenesis and acetyl-CoA levels.
In the present study of VPA-treated rats, the mean serum and muscle free carnitine concentrations decreased and the mean acylcarnitine concentration increased relative to control animals.
NISHIDA ET AL. In VPA-treated rats, urinary acylcarnitine excretion increased and free carnitine excretion remained unchanged compared to controls. These findings support the view that free carnitine buffers excessive acyl-CoA derivatives, which are converted to nontoxic acylcarnitine derivatives and excreted in urine (15). The normal levels of liver carnitine in the VPA group may depend on sufficient production from y-butyrobetaine in the liver, because the rats were permitted to feed ad libitum. Although the serum free carnitine concentration decreased in VPAtreated rats, there was no difference in urinary free carnitine concentration between the control and the VPA-treated animals. It is likely that the reabsorption of free carnitine in renal tubules was inhibited (16, 17) . The reduced free carnitine levels in serum and the muscle of the VPA group may indicate suppression of P-oxidation in mitochondria. L-Carnitine act as a camer for the entry of fatty acids into the mitochondria, where they undergo p-oxidation (1 8). In VPA plus L-carnitine-treated rats in the present studies, the muscle carnitine concentration was similar to that of control that the inhibited P-oxidation in the mitochondria of VPAtreated rats was reversed by the supplementation of L-carnitine. This suggestion is supported by the following results: 1) the serum beta-OH-butyrate levels in VPA plus L-carnitine treated rats was higher than that in VPA-treated rats and 2) urinary acylcarnitine excretion after day 4 to 7 in the VPA plus Lcarnitine treated rats was lower than in VPA-treated rats which showed remarkably increased levels relative to controls. In the L-carnitine-supplemented animals carnitine concentrations in the serum and the liver increased, although free carnitines in the RBC and the muscle did not. Most tissues have a carnitine concentration that is more than 10-fold higher than that of blood plasma, and the turnover times for carnitine in liver and skeletal muscle are 1.3 and 105 h, respectively (23). The differences in carnitine concentrations in the present study may be explained by the turnover times.
Table 2. Urinary excretion of carnitine (~m o l l g creatinine) in four groups
Our results suggest that the inhibition of P-oxidation due to VPA medication may be relieved with L-carnitine supplementation. Ater et al. (24) demonstrated that L-carnitine did not significantly alter the anticonvulsant properties of VPA. Clinically, L-carnitine supplementation might prevent VPA-induced hepatotoxicity in epileptic patients (2, 6) and might be effective in treating patients with Reye's syndrome and Reye-like syndrome, in whom @-oxidation in the mitochondria is inhibited. 
